CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: As documented, CML LSCs reside within the CD34+/CD38−/Lin− fraction and are characterized by an aberrant expression of specific surface markers, such as IL1RAP, CD25, CD93, and CD26 (DPPV) (Raspadori et al., 2019).